TNSN00027A1 - Inhibiteurs de l'aspartyle protease - Google Patents

Inhibiteurs de l'aspartyle protease

Info

Publication number
TNSN00027A1
TNSN00027A1 TNTNSN00027A TNSN00027A TNSN00027A1 TN SN00027 A1 TNSN00027 A1 TN SN00027A1 TN TNSN00027 A TNTNSN00027 A TN TNSN00027A TN SN00027 A TNSN00027 A TN SN00027A TN SN00027 A1 TNSN00027 A1 TN SN00027A1
Authority
TN
Tunisia
Prior art keywords
hiv
aspartyle
compounds
protease
relates
Prior art date
Application number
TNTNSN00027A
Other languages
English (en)
Inventor
A Stammers Timothy
G Sherrill Ronald
S Furfine Eric
Maltais Francois
F Miller John
Samano Vicente
Spaltenstein Andrew
Webster Andrews Clarence Iii
R Hale Michael
T Baker Christopher
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of TNSN00027A1 publication Critical patent/TNSN00027A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENTION SE RAPPORTE A UNE NOUVELLE CLASSE DE SULFONAMIDES QUI SONT DES INHIBITEURS DE L'ASPARTYLE PROTEASE. DANS UNE REALISATION, CETTE INVENTION SE RAPPORTE A UNE NOUVELLE CLASSE D'INHIBITEURS DE L'ASPARTYLE PROTEASE DU HIV CARACTERISES PAR DES CARACTERISTIQUES STRUCTURELLES ET PHYSICO-CHIMIQUES SPECIFIQUES. CETTE INVENTION SE RAPPORTE AUSSI A DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES. LES COMPOSES ET LES COMPOSITIONS PHARMACEUTIQUES DE CETTE INVENTION SONT PARTICULIEREMENT BIEN ADAPTES A L'INHIBITION DE L'ACTIVITE DE LA PROTEASE DU HIV-1 ET DU HIV-2 ET PAR CONSEQUENT, ILS PEUVENT ETRE UTILISES AVANTAGEUSEMENT COMME AGENTS ANTIVIRAUX CONTRE LES VIRUS HIV-1 ET HIV-2. CETTE INVENTION SE RAPPORTE AUSSI A DES METHODES POUR INHIBER L'ACTIVITE DE L'ASPARTYLE PROTEASE DU HIV AU MOYEN DES COMPOSES DE CETTE INVENTION ET DES METHODES D'ANALYSE DE COMPOSES POUR METTRE EN EVIDENCE UNE ACTIVITE ANTI-HIV.
TNTNSN00027A 1999-02-12 2000-02-09 Inhibiteurs de l'aspartyle protease TNSN00027A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12004799P 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
TNSN00027A1 true TNSN00027A1 (fr) 2005-11-10

Family

ID=37874715

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00027A TNSN00027A1 (fr) 1999-02-12 2000-02-09 Inhibiteurs de l'aspartyle protease

Country Status (4)

Country Link
US (4) US6319946B1 (fr)
CO (1) CO5261510A1 (fr)
TN (1) TNSN00027A1 (fr)
TW (1) TWI260322B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
TNSN00027A1 (fr) * 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
AU2003202914A1 (en) * 2002-01-07 2003-07-24 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
WO2003091264A2 (fr) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Inhibiteurs non nucleosidiques de la transcriptase inverse
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
WO2005002626A2 (fr) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7300924B2 (en) * 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
WO2005000249A2 (fr) * 2003-06-27 2005-01-06 Smithkline Beecham Corporation Preparation de composes chimiques
WO2005044308A1 (fr) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Analogues phosphonates d'antimetabolites
WO2005044279A1 (fr) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Conjugues phosphonate / inhibiteur de purine nucleoside phosphorylase
WO2005042773A1 (fr) * 2003-10-24 2005-05-12 Gilead Sciences, Inc. Procedes et compositions permettant d'identifier des composes therapeutiques
US20070281907A1 (en) * 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
BRPI0417988A (pt) * 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
JP2007528423A (ja) * 2004-03-11 2007-10-11 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
US7378441B2 (en) 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
EP2139883A4 (fr) * 2007-03-23 2011-06-22 Univ Massachusetts Inhibiteurs de la protéase du vih-1
US8569364B2 (en) 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
EP2723758B1 (fr) 2011-06-21 2018-06-20 Alnylam Pharmaceuticals, Inc. Compositions d'arni faisant intervenir la protéine 3 de type angiopoïétine (angptl3) et leurs procédés d'utilisation
WO2012178033A2 (fr) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Arnsi de serpina1 : compositions et méthodes de traitement
WO2013003801A2 (fr) 2011-06-29 2013-01-03 The Trustees Of Columbia University In The City Of New York Inhibiteur de la connectivité neuronale lié à la susceptibilité à la schizophrénie et à un dysfonctionnement cognitif
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
WO2014075093A1 (fr) * 2012-11-09 2014-05-15 The Trustees Of Columbia University In The City Of New York Inhibiteurs du récepteur 2 de peptide inhibiteur vasoactif du système nerveux central
IL292159B1 (en) 2012-12-05 2026-04-01 Alnylam Pharmaceuticals Inc PCSK9 iRNA compositions and methods of using them
IL288931B2 (en) 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
EA038792B1 (ru) 2013-05-22 2021-10-20 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR102234623B1 (ko) 2013-05-22 2021-04-02 알닐람 파마슈티칼스 인코포레이티드 Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
CN113057959B (zh) 2014-02-11 2024-07-16 阿尔尼拉姆医药品有限公司 己酮糖激酶（KHK）iRNA组合物及其使用方法
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
AU2015264038B2 (en) 2014-05-22 2021-02-11 Alnylam Pharmaceuticals, Inc. Angiotensinogen (AGT) iRNA compositions and methods of use thereof
WO2016039403A1 (fr) * 2014-09-11 2016-03-17 塩野義製薬株式会社 Inhibiteur prolongé de la protéase du vih
WO2016040589A1 (fr) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation
WO2016061487A1 (fr) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques de ciblage d'acide aminolévulinique synthase-1 (alas1) et utilisations de ceux-ci
EP3212794B1 (fr) 2014-10-30 2021-04-07 Genzyme Corporation Agents polynucléotidiques ciblant serpinc 1 (at3) et leurs méthodes d'utilisation
JP2017535552A (ja) 2014-11-17 2017-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
CA2976445A1 (fr) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Compositions d'arni du gene codant pour la proteine 3 contenant un domaine phospholipase de type patatine (pnpla3) et leurs procedes d'utilisation
CN115927335A (zh) 2015-04-13 2023-04-07 阿尔尼拉姆医药品有限公司 类血管生成素3（ANGPTL3）iRNA组合物及其使用方法
JP6695902B2 (ja) 2015-05-06 2020-05-20 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法
WO2016201301A1 (fr) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation
EP3310918B1 (fr) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant l'hydroxyacide oxydase (glycolate oxydase, hao1) et procédés d'utilisation de ceux-ci
WO2017048620A1 (fr) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Agents de polynucléotide ciblant un domaine de phospholipase de type patatine contenant 3 (pnpla3) et leurs procédés d'utilisation
KR20180095843A (ko) 2015-12-07 2018-08-28 젠자임 코포레이션 Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
EP3387129A1 (fr) 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. COMPOSITIONS D'ARNi CHAPERON (SCAP) DE LA PROTÉINE SREBP (STEROL REGULATORY ELEMENT BINDING PROTEIN), ET PROCÉDÉS D'UTILISATION ASSOCIÉS
EP3469083A1 (fr) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. Compositions d'arni du composant c5 du complément et leurs méthodes d'utilisation pour traiter l'hémoglobinurie paroxystique nocturne (hpn)
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
WO2018112320A1 (fr) 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Méthodes de traitement ou de prévention de maladies associées à ttr à l'aide de compositions d'arni de transthyrétine (ttr)
TW202434265A (zh) 2017-07-10 2024-09-01 美商健贊公司 於患有血友病之個體中治療出血事件之方法及組成物
US11564921B2 (en) 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
JP7625512B2 (ja) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
MX2021008628A (es) 2019-01-16 2021-11-17 Genzyme Corp Composiciones de arni para serpinc1 y metodos de uso de las mismas.
WO2021154941A1 (fr) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Compositions d'arni du composant c5 du complément destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique (sla)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604402A (en) 1984-03-30 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxy substituted ureido amino and imino acids
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
EP0885880A3 (fr) 1992-10-30 1999-10-06 G.D. Searle & Co. Dérivés d'acide sulfamique sulfonylalkanoylaminohydroxyéthylamino utiles comme inhibiteurs des protéases rétrovirales
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0715618B1 (fr) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino-sulfonamides aptes a etre utilises comme inhibiteurs de protease retrovirale
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2210889C (fr) * 1995-01-20 2007-08-28 G.D. Searle & Co. Inhibiteurs hydroxyethylamino contenant des bis-sulfinamides utilises pour inhiber des proteases retrovirales
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
TNSN00027A1 (fr) * 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease

Also Published As

Publication number Publication date
US7919523B2 (en) 2011-04-05
CO5261510A1 (es) 2003-03-31
US20090042973A1 (en) 2009-02-12
US20020198388A1 (en) 2002-12-26
US6319946B1 (en) 2001-11-20
US20040127488A1 (en) 2004-07-01
US6617350B2 (en) 2003-09-09
TWI260322B (en) 2006-08-21
US7442718B2 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
TNSN00027A1 (fr) Inhibiteurs de l'aspartyle protease
TNSN00129A1 (fr) Inhibiteurs de l'aspartyle protease
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
CA2217737A1 (fr) Sulfamides contenant tetrahydrofurane (thf) et agissant comme inhibiteurs de la protease aspartyle
MY115797A (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
EP0885887A3 (fr) Sulfonamides inhibiteurs d'aspartyle protéase du VIH
ATE237587T1 (de) 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
MX9603909A (es) Derivados de sulfonamida como inhibidores de proteasa aspartilo.
YU39800A (sh) Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze
HUP9903673A2 (hu) A HIV CNS-hatásainak kezelése VX-478-cal önmagában vagy AZT-vel vagy 3TC-vel kombinációban
WO2000047551A3 (fr) Inhibiteurs d'aspartyle protease
NO974147D0 (no) Heterocykelkarbonyl aminosyre hydroksyetylamino sulfonamid retroviral protease
DK0763017T3 (da) N-(3-amino-2-hydroxybutyl)sulfonamidderivater som HIV-proteaseinhibitorer
CA2245206A1 (fr) Utilisation d'un inhibiteur d'acides amines excitateurs dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
MY135869A (en) Inhibitors of aspartyl protease
MX9708055A (es) Inhibidores de aspartil proteasa consistentes en sulfonamida que contiene heterociclo oxigenado.
MX9708057A (es) Sulfonamidas que contienen thf inhibidoras de la aspartilproteasa.
TNSN03088A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
TH35214A (th) ตัวยับยั้งแอสพาร์ทิลโปรทีเอส
WO1998040357A3 (fr) Inhibiteurs de la protease du vih